Novartis Ag

Zaixing Li

Liladhar Murlidhar Waykole

James Neef

Malay Ghosh

Dietmar Flubacher

Tingying Zhu

Tejaskumar Pankajbhai Pathak

Amir Masoud Sadaghiani

Xilin Zhou

Cale Ry McAlister

Chui Lu

Jeremiah Douglas Foutch

Jens Sören Worthmann

Christoph Bucher

Sung David C Kim

Danuta Lubicka

Johannes Franz Kluge

Hye-Yeon Park

Michael Mutz

Mika Lindvall

Heinz Ernst Moser

Robert Lowell Simmons

Folkert Reck

Anthony Casarez

Andreas Fisch

Bernd Ulrich Riebesehl

Vijay Sethuraman

Marc Schoenhentz

Eric Aubin

Cornelius Stephen Harlacher

The present disclosure provides for a compound according to formula (I)

Methyl (R)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[B]pyridine-3-carboxylate and methyl 2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyrodine-3-carboxylate as Ca1.2 activators

The present invention relates to crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinanmide and to processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-trifluoromethyl)isonicotinamide, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of cancers.

Crystalline forms of-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as Raf inhibitors for the treatment of cancer

The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Ca1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.

Methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[b]pyridine-3-carboxylate and methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylate as CAV1.2 activators

The present disclosure provides salts of lipoic acid choline ester (LACE), crystalline forms thereof, and methods of use thereof. The present disclosure further provides pharmaceutical compositions of LACE salts and methods of use thereof.

Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using same

The invention provides new solid forms, salts and polymorphs of 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to herein as Compound X), pharmaceutical compositions containing them, and processes for their manufacture and use in therapy.

Salts and solid forms of a monobactam antibiotic

Growing community of inventors

Yangpu District, China

Zaixing Li